BRPI0418122A - formulação farmacêutica de liberação controlada - Google Patents

formulação farmacêutica de liberação controlada

Info

Publication number
BRPI0418122A
BRPI0418122A BRPI0418122-0A BRPI0418122A BRPI0418122A BR PI0418122 A BRPI0418122 A BR PI0418122A BR PI0418122 A BRPI0418122 A BR PI0418122A BR PI0418122 A BRPI0418122 A BR PI0418122A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
controlled release
release pharmaceutical
dose
controlled
Prior art date
Application number
BRPI0418122-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Polonca Kuhar
Sirca Judita
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of BRPI0418122A publication Critical patent/BRPI0418122A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0418122-0A 2003-12-23 2004-12-22 formulação farmacêutica de liberação controlada BRPI0418122A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200300317A SI21637A (sl) 2003-12-23 2003-12-23 Farmacevtska oblika z nadzorovanim sproščanjem
PCT/SI2004/000044 WO2005060939A2 (fr) 2003-12-23 2004-12-22 Formulation pharmaceutique a liberation controlee

Publications (1)

Publication Number Publication Date
BRPI0418122A true BRPI0418122A (pt) 2007-04-17

Family

ID=34709497

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418122-0A BRPI0418122A (pt) 2003-12-23 2004-12-22 formulação farmacêutica de liberação controlada

Country Status (12)

Country Link
US (1) US20070141149A1 (fr)
EP (1) EP1699439A2 (fr)
JP (1) JP2007516282A (fr)
CN (1) CN1897923A (fr)
AR (1) AR048138A1 (fr)
AU (1) AU2004305422B2 (fr)
BR (1) BRPI0418122A (fr)
CA (1) CA2547586C (fr)
RU (1) RU2447884C2 (fr)
SI (1) SI21637A (fr)
WO (1) WO2005060939A2 (fr)
ZA (1) ZA200603656B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006232696A (ja) * 2005-02-23 2006-09-07 Taisho Pharm Ind Ltd 徐放性製剤
JP5524624B2 (ja) * 2007-11-16 2014-06-18 旭化成ケミカルズ株式会社 水系フィルムコーティング液、および、フィルムコーティング顆粒、ならびに、これを用いた錠剤
KR101689688B1 (ko) * 2008-11-18 2016-12-26 유씨비 파마, 에스.에이. 2­옥소­1­피롤리딘 유도체를 포함하는 지연 방출형 제형
CN118284408A (zh) 2021-10-25 2024-07-02 法玛利德尔公司 他达拉非经口混悬剂
CN115300506A (zh) * 2022-08-11 2022-11-08 南京红地生物科技有限公司 含有坦索罗辛和米拉贝隆的复方制剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5041430A (en) * 1989-09-18 1991-08-20 Du Pont Mereck Pharmaceutical Company Oral anticoagulant/platelet inhibitor low dose formulation
ZA919510B (en) * 1990-12-05 1992-10-28 Smithkline Beecham Corp Pharmaceutical compositions
EP0520119A1 (fr) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Composition à base de diclofenac pour l'administration orale
GB9117361D0 (en) * 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
AU8604098A (en) * 1997-08-01 1999-02-22 Acushnet Company Golf ball and method of making same
EA002806B1 (ru) * 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Многоединичные композиции с модифицированным высвобождением нестероидных противовоспалительных лекарственных веществ (nsaid)
US6602522B1 (en) * 1997-11-14 2003-08-05 Andrx Pharmaceuticals L.L.C. Pharmaceutical formulation for acid-labile compounds
WO2001062195A1 (fr) * 2000-02-24 2001-08-30 Advancis Pharmaceutical Corporation Compositions antibiotiques et antifongiques
US6610328B2 (en) * 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
KR100530546B1 (ko) * 2001-07-27 2005-11-23 아스텔라스세이야쿠 가부시키가이샤 구강내에서 신속하게 붕괴되는 정제용 서방성 미립자가함유된 조성물 및 그의 제조 방법
KR20040081446A (ko) * 2002-01-04 2004-09-21 아이박스 리서치, 인코포레이티드 글리피지드의 서방성을 위한 약물 전달 체계
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin

Also Published As

Publication number Publication date
EP1699439A2 (fr) 2006-09-13
SI21637A (sl) 2005-06-30
RU2447884C2 (ru) 2012-04-20
CA2547586C (fr) 2012-12-04
AR048138A1 (es) 2006-04-05
JP2007516282A (ja) 2007-06-21
ZA200603656B (en) 2007-09-26
AU2004305422A1 (en) 2005-07-07
RU2006126786A (ru) 2008-01-27
WO2005060939A3 (fr) 2005-12-29
CN1897923A (zh) 2007-01-17
WO2005060939A2 (fr) 2005-07-07
CA2547586A1 (fr) 2005-07-07
US20070141149A1 (en) 2007-06-21
AU2004305422B2 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
PT1256340E (pt) Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
HUP0402217A2 (hu) Platinaszármazékot tartalmazó gyógyászati készítmények
BRPI0313424B8 (pt) forma de dosagem e processo para a preparação de uma forma de dosagem
BRPI0015284B8 (pt) formulações de hidrocodona de liberação controlada
Mendel et al. Therapy with hyperbaric oxygen and cefazolin for experimental osteomyelitis due to Staphylococcus aureus in rats
NO20055880L (no) Memantin orale doseringsformer
WO2004112711A3 (fr) Composition orale a liberation prolongee
MXPA02012793A (es) Composicion de dilatacion rapida para la retencion gastrica y la liberacion controlada de agentes terapeuticos y formas de dosificacion de la composicion.
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
BRPI0414500A (pt) formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
BR0308229A (pt) Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio
BRPI0418122A (pt) formulação farmacêutica de liberação controlada
BR9915729A (pt) Amidas Èmega de n-arilsulfonil-aminoácido
BR0115390A (pt) Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica
BR0315659A (pt) Composição farmacêutica oral para administração uma vez ao dia para a liberação controlada de tramadol ou um sal do mesmo
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
TNSN06072A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
EP0521057A1 (fr) Compositions pharmaceutiques contenant de l'ipriflavone, procede de preparation et utilisations pharmaceutiques de ces compositions.
BRPI0417796A (pt) preparado efervescente de uma substáncia básica de efeito medicinal
BRPI0509305A (pt) uso de um sensibilizador insulìnico, composição farmecêutica, e , kit
BRPI0617184A2 (pt) formulação de pralnacasan com liberação retardada
DK1265629T3 (da) Anvendelse af væksthormon i lav dosis
AR029327A1 (es) Uso de la levobupivacaina para la preparacion de medicamentos de aplicacion en el anestesiamiento de pacientes sujetos a intervencion de cirugia mayor

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.